Trial Profile
A Randomised, Open-label, Single-centre, Two-period, Cross-over Trial Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2016
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 30 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.